Vet Medicine: Longevity Pills, Vet Shortages and Bills — 2026-09-25
The UK's CMA veterinary market remedies became a legally binding Order on 22 September 2026, bringing a £21 prescription fee cap and mandatory published price lists for pet owners. In the US, Loyal's canine longevity programme advanced with new FDA support reported this week, while rural America's vet shortage remains acute. Germany's GOT fee-schedule dispute continues to weigh on practice capacity.
Vet Medicine: Longevity Pills, Vet Shortages and Bills — 2026-09-25
Top developments
CMA vet remedies become legally binding in the UK
The CMA's vets market remedies became a legal Order on 22 September 2026, starting compliance clocks for a £21 prescription fee cap, published price lists, written estimates and itemised bills. Larger firms must roll out reforms by December 2026, while small firms have 12 months to implement the changes. Around 11 new rule changes are now "in force," aimed at curbing what the Mirror calls "excessive" charges from big corporate chains.
Loyal's second longevity drug receives FDA support
New coverage this week reports that Loyal's STAY study — its second canine healthy-lifespan-extension candidate — has received FDA support. The STAY trial dosed its first dog, a Whippet named Boo, in December 2023 and is described by Loyal as the first and only FDA-concurred longevity clinical trial and the largest veterinary trial in history. The programme is also notable for using trial-naïve practice sites:育种 clinical research experience are participating.
LOST — correction: the STAY study uses many veterinarians who have never previously participated in clinical research, broadening the trial infrastructure for future vet drug development.
Rural America's veterinary shortage deepens
Reporting published this week (Minot, North Dakota) highlights how rural counties across the US face a growing shortage of veterinary practices, driven by surging pet ownership, too few new graduates, burnout and economic pressure. The result: long waits, limited services and higher costs for pet owners in underserved areas.
Pet insurance gaps leave owners exposed
New commentary this week argues that pet insurance is booming, but most US states have no rules requiring insurers to clearly disclose exclusions — meaning many owners discover coverage gaps only after a claim is denied. For practices, insurance remains central to affordability: the Pawlicy Advisor/AAHA State of the Industry report (covered recently) found every affordability measure worsening year over year.
Local view
German-language coverage this month continues to flag tension over the Tierärzte fee schedule: honestdog.de reports that the dispute over GOT rates is worsening practice capacity shortages ("Streit um GOT-Sätze verschärft Engpass in tierärztlichen Praxen"), with owners facing Notdienst (out-of-hours) surcharges of up to 4x the standard GOT rate.
Context & numbers
- Global veterinary drugs market: valued at USD 30.54 billion in 2025, projected USD 53.05 billion by 2034 at a 6.44% CAGR (Maximize Market Research).
- UK prescription fee cap: £21 under the new CMA Order.
- Loyal's LOY-002 trial enrolled its target of 1,000 dogs; an earlier FDA efficacy determination of "reasonable expectation of effectiveness" was based on a study of 452 companion dogs across 84 breeds.
- German vet costs: general consultation from ~€30 up to €5,000 for emergency surgery under GOT rules.
On the radar
- December 2026: deadline for larger UK vet firms to comply fully with the CMA Order; smaller firms have until roughly September 2027.
- Watch for Loyal's final technical section (effectiveness/quality) milestones toward a potential conditional approval for LOY-002.
- The UK SPVS 2026 salary survey remains open — results will inform workforce and pay benchmarks.
- Pet insurance regulatory scrutiny in the US could tighten disclosure rules, following rising complaint coverage (advocacy commentary, not regulator action yet).
This content was collected, curated, and summarized entirely by AI — including how and what to gather. It may contain inaccuracies. Crew does not guarantee the accuracy of any information presented here. Always verify facts on your own before acting on them. Crew assumes no legal liability for any consequences arising from reliance on this content.
Powered by
